Evidence map›Paper›PMID 32319538›Full record

ReviewInternational journal of molecular medicine2020

Zinc and respiratory tract infections: Perspectives for COVID‑19 (Review).

Anatoly V Skalny, Lothar Rink, Olga P Ajsuvakova, Michael Aschner, Viktor A Gritsenko, Svetlana I Alekseenko, Andrey A Svistunov, Demetrios Petrakis, Demetrios A Spandidos, Jan Aaseth and 2 more

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04777981 (Efficacy of Cannabidiol in Combination With Red Algae), which is not on this map. Cited by 252 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
252citing papers in PubMed, 5 pooled it
47.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04777981 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Efficacy of Cannabidiol in Combination With Red Algae (CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection PASC

TypeinterventionalSponsorAnewsha Therapeutics Inc.Ran2022 to 2022Enrolled60ConditionsCOVID-19, SARArmsCBDRA60 supplement, Placebo
3 · Its place in the literature

Who cites it

252 citing papers in PubMed, 5 syntheses or guidelines pooled it, 439 citations in OpenAlex.

  1. Pooled it
  2. Potential ofBioMed research international · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Toxic metal exposure as a possible risk factor for COVID-19 and other respiratory infectious diseases.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2020
    Pooled it
  6. COVID-19 prophylaxis with doxycycline and zinc in health care workers: a prospective, randomized, double-blind clinical trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Trial
  7. Trial
  8. Trial
  9. Review
  10. Serum zinc level independently predicts need for inpatient intubation among patients hospitalized with COVID-19: A prospective observational study.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026
    Observational
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Zinc in psychosis (Review).Molecular medicine reports · 2025
    Review
  17. Article
  18. Review
  19. Article
  20. Review

192 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Anatoly V SkalnyI.M. Sechenov First Moscow State Medical University (Sechenov University), 119146 Moscow, Russia.
Lothar RinkInstitute of Immunology, Medical Faculty, RWTH Aachen University, D-52062 Aachen, Germany.
Olga P AjsuvakovaYaroslavl State University, 150003 Yaroslavl, Russia.
Michael AschnerI.M. Sechenov First Moscow State Medical University (Sechenov University), 119146 Moscow, Russia.
Viktor A GritsenkoInstitute of Cellular and Intracellular Symbiosis, Russian Academy of Sciences, 460000 Orenburg, Russia.
Svetlana I AlekseenkoI.I. Mechnikov North‑Western State Medical University, 191015 St. Petersburg, Russia.
Andrey A SvistunovI.M. Sechenov First Moscow State Medical University (Sechenov University), 119146 Moscow, Russia.
Demetrios PetrakisCenter of Toxicology Science and Research, Medical School, University of Crete, 71409 Heraklion, Greece.
Demetrios A SpandidosLaboratory of Clinical Virology, Medical School, University of Crete, 71409 Heraklion, Greece.
Jan AasethI.M. Sechenov First Moscow State Medical University (Sechenov University), 119146 Moscow, Russia.
Aristidis TsatsakisI.M. Sechenov First Moscow State Medical University (Sechenov University), 119146 Moscow, Russia.
Alexey A TinkovI.M. Sechenov First Moscow State Medical University (Sechenov University), 119146 Moscow, Russia.
Sechenov University · RUUniversity of Crete · GRInstitute of Cellular and Intracellular Symbiosis · RUNorth-Western State Medical University named after I.I. Mechnikov · RURWTH Aachen University · DEYaroslavl State University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In view of the emerging COVID‑19 pandemic caused by SARS‑CoV‑2 virus, the search for potential protective and therapeutic antiviral strategies is of particular and urgent interest. Zinc is known to modulate antiviral and antibacterial immunity and regulate inflammatory response. Despite the lack of clinical data, certain indications suggest that modulation of zinc status may be beneficial in COVID‑19. In vitro experiments demonstrate that Zn2+ possesses antiviral activity through inhibition of SARS‑CoV RNA polymerase. This effect may underlie therapeutic efficiency of chloroquine known to act as zinc ionophore. Indirect evidence also indicates that Zn2+ may decrease the activity of angiotensin‑converting enzyme 2 (ACE2), known to be the receptor for SARS‑CoV‑2. Improved antiviral immunity by zinc may also occur through up‑regulation of interferon α production and increasing its antiviral activity. Zinc possesses anti‑inflammatory activity by inhibiting NF‑κB signaling and modulation of regulatory T‑cell functions that may limit the cytokine storm in COVID‑19. Improved Zn status may also reduce the risk of bacterial co‑infection by improving mucociliary clearance and barrier function of the respiratory epithelium, as well as direct antibacterial effects against S. pneumoniae. Zinc status is also tightly associated with risk factors for severe COVID‑19 including ageing, immune deficiency, obesity, diabetes, and atherosclerosis, since these are known risk groups for zinc deficiency. Therefore, Zn may possess protective effect as preventive and adjuvant therapy of COVID‑19 through reducing inflammation, improvement of mucociliary clearance, prevention of ventilator‑induced lung injury, modulation of antiviral and antibacterial immunity. However, further clinical and experimental studies are required.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19HumansPandemicsPneumoniaRespiratory Tract InfectionsRisk FactorsSARS-CoV-2ZincAngiotensin-Converting Enzyme 2Zinc

Identifiers

PMID32319538
PMCPMC7255455
OpenAlexW3016268727

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.